Orgenesis Receives $1.5 Million Term Loan to Help Fund Breakthrough Innovation in Diabetes Research

WHITE PLAINS, NY (Marketwired Jun 25, 2014) Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and re-generative medicine, announced today that it raised $1.5 million via a senior secured term loan facility. This infusion of funding allows us to aggressively move forward with the development of new medical technologies and cell therapies for the treatment of diabetes, said Vered Caplan, chairperson and CEO of Orgenesis. The focus will immediately be on our Belgium subsidiary, Orgenesis SPRL where all the funds will be used to advance our research on cellular trans-differentiation as a potential curative treatment for serious diseases such as type 1 diabetes and quicken our pace toward human trials. This financing also opens the door for future funding and grants by making Orgenesis eligible to tap into additional government financing and grant opportunities in Europe. Cellular trans-differentiation is a breakthrough innovation Orgenesis has developed to
http://bit.ly/1qw9TC4